[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Structural Heart Devices Global Market – Forecast To 2027

July 2020 | 453 pages | ID: S58384E3F75EN
IQ4I Research & Consultancy Pvt. Ltd.

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Structural heart devices consist of the various therapeutic interventional devices used to efficiently and economically close an abnormal communication between the heart chambers or to reconstruct or replace a diseased or degenerated heart valve through the adoption of a multidisciplinary remedial approach. Compared to the traditional highly invasive open heart surgical repair and replacement procedures, the current minimally invasive transcatheter therapeutic procedures with highly efficient, technologically advanced products assure patients and healthcare providers with improved efficiency, effectiveness and quicker restoration of the non coronary physical defects of the heart. Increased utilization of the various structural heart therapeutic products for the numerous and varied types of structural heart diseases among the patients, elevating inclination of the value centric global patient pool towards the minimally invasive, technologically advanced structural heart products with better therapeutic outcomes and the need to reduce hospitalization duration and ease and improve the patient’s condition quickly through durable structural heart interventional products are fuelling the structural heart devices global market.

As estimated by IQ4I Research, the structural heart devices global market is expected to reach $17,433.4 million by 2027 growing at a double digit CAGR from 2020 to 2027, due to elevating prevalence of various kinds of structural heart diseases, increasing expanded indication approval for various transcatheter structural heart products, persistently increasing geriatric population burdened with various kinds of degenerative valvular hear diseases, increasing demand for highly efficient, minimally invasive structural heart therapeutic products from the value centric patient population, increasing R&D spending for developing innovative and technologically advanced products, growing economies and increasing demand for better healthcare facilities in emerging markets. The structural heart devices market is segmented by product (product type), indication and geography.

Based on the product, the structural heart devices global market is segmented into structural heart repair and structural heart replacement devices. Among these products, structural heart replacement segment is the largest product segment in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027. Structural heart repair devices segment is the fastest emerging segment growing at a low teen CAGR from 2020 to 2027. Among the various structural heart repair products like Annuloplasty repair devices, valvuloplasty devices, occluders, Transcatheter mitral valve repair devices and other repair devices like chordal implants, transcatheter mitral valve repair product segment accounted for the largest revenue in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027. Other structural heart repair device segment is the fastest emerging segment and is expected to exhibit exponential growth during the forecasted period. Among the structural heart replacement devices, Transcatheter valve replacement device segment accounted for the largest revenue in 2020 and is expected to grow at mid teen CAGR from 2020 to 2027. In the surgical valve replacement device global market by product type, tissue valve segment accounted for the largest revenue of in 2020. Among the Transcatheter valve replacement devices, Transcatheter aortic valve replacement (TAVR) device segment holds the largest share in 2020 and is expected to grow at low teen CAGR from 2020 to 2027 while Transcatheter mitral valve replacement (TMVR) product segment is the fastest emerging segment and is expected to show an exponential growth during the forecasted period.

Based on the indication, the structural heart devices global market is segmented into heart valve diseases, congenital heart diseases and other structural heart diseases. Among these, the heart valve disease segment commanded the largest revenue in 2020 and is expected to grow at a low teen CAGR from 2020 to 2027. Among the various heart valve diseases, aortic valve disease segment holds the largest share in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027 while mitral valve disease segment is the fastest emerging segment and is expected to show mid teen CAGR during the forecasted period.

Based on the region, the structural heart devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, Italy and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Turkey, Rest of Latin America and Middle East & Africa). North America accounted for the largest revenue in 2020 and is expected to grow at a double digit CAGR from 2020 to 2027 due to increasing prevalence of structural heart diseases, escalating geriatric population burdened with degenerative valvular heart diseases, increasing demand for highly efficient, durable, minimally invasive and technologically advanced structural heart therapeutic products from the value centric patient population, increasing R&D spending for developing innovative and technologically advanced products, substantial insurance coverage for the interventional procedures there.

The Asia-Pacific is the fastest growing region in structural heart devices market in 2020 and is expected to grow at a mid teen CAGR from 2020 to 2027 due to elevating structural heart disease burden in the region, escalating geriatric population, increasing demand for better healthcare facilities, increasing penetration of reimbursement schemes in developing countries, elevating demand for highly efficient and minimally invasive products from the value centric patient population, growing economies of the region, availability of various kinds of structural heart therapeutic products, increasing patient awareness of these products and increasing medical tourism prospects of the region.

The structural heart devices global market is consolidated with few companies dominating the market that offers fewer opportunities for entry for small and medium-sized companies with distinct products in the market. The top players in structural heart devices market are Edwards Lifesciences Corporation (U.S.), Medtronic PLC (Ireland), Abbott Laboratories (U.S.), Livanova PLC (U.K.), Boston Scientific Corporation (U.S.), Cryolife Inc. (U.S.), AtriCure, Inc. (U.S.), Venus Medtech (Hangzhou) Inc (China), Lifetech Scientific Corporation (China), NuMed Inc. (U.S.) and others.

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
  • North America
    • U.S.
    • Rest of North America
  • Europe
    • Germany
    • Italy
    • France
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of APAC
  • Rest of the World (RoW)
    • Brazil
    • Turkey
    • Rest of LATAM & MEA
1 EXECUTIVE SUMMARY

2 INTRODUCTION

2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
  2.6.1 MARKET SIZE ESTIMATION
  2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
  2.6.3 SECONDARY SOURCES
  2.6.4 PRIMARY SOURCES
  2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
  2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
  2.6.7 ASSUMPTIONS

3 MARKET ANALYSIS

3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
  3.3.1 DRIVERS AND OPPORTUNITIES
    3.3.1.1 Increasing prevalence of structural heart diseases
    3.3.1.2 Increasing adoption of minimally invasive surgery for structural heart diseases
    3.3.1.3 Increasing expanded indication approval of tavr products
    3.3.1.4 Vast structural heart product pipeline and significant r&d investments
    3.3.1.5 Emergence of technologically advanced products
    3.3.1.6 Persistently escalating geriatric population with structural heart diseases
    3.3.1.7 Acquisitions to open an array of opportunities for the market to flourish
    3.3.1.8 Availability of advanced imaging techniques and increasing access to neonatal screening programs
  3.3.2 RESTRAINTS AND THREATS
    3.3.2.1 Lack of skilled and trained professionals
    3.3.2.2 High cost of the advanced structural heart devices
    3.3.2.3 Adverse effects of structural heart devices
    3.3.2.4 Unfavourable reimbursement policies in developing nations
    3.3.2.5 Stringent regulatory bodies guiding structural heart device manufacturers
3.4 REGULATORY AFFAIRS
  3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
    3.4.1.1 ISO 9001: 2015 quality management system
    3.4.1.2 ISO 14644-1 clean room standards
    3.4.1.3 ISO 13485 medical devices
    3.4.1.4 ISO 10993 biological evaluation of medical devices
    3.4.1.5 ISO 14971: risk management of medical devices
    3.4.1.6 ISO 5840 : heart valve validation
    3.4.1.7 IEC 60601-1 medical electrical equipment standard
    3.4.1.8 IEC 60601-1-11 home care safety
  3.4.2 ASTM INTERNATIONAL STANDARDS
  3.4.3 U.S.
  3.4.4 CANADA
  3.4.5 EUROPE
  3.4.6 JAPAN
  3.4.7 CHINA
  3.4.8 INDIA
3.5 REIMBURSEMENT SCENARIO
3.6 PATENT TRENDS
3.7 TECHNOLOGICAL ADVANCEMENTS
  3.7.1 INTRODUCTION
  3.7.2 POLYMERIC HEART VALVES
  3.7.3 ULTRASOUND DEVICE FOR AORTIC STENOSIS
  3.7.4 BIODEGRADABLE OCCLUDERS
  3.7.5 VALVE IN VALVE PROCEDURE
  3.7.6 ADJUSTABLE ANNULOPLASTY RINGS
  3.7.7 SUTURELESS AORTIC VALVE SYSTEMS
3.8 UPCOMING TECHNOLOGIES
  3.8.1 BIOENGINEERED LIVING OR REGENERATIVE HEART VALVES
  3.8.2 3-D BIOPRINTED HEART VALVE
3.9 CLINICAL TRIALS
3.10 FUNDING SCENARIO
3.11 STRUCTURAL HEART DEVICES - PRODUCT PIPELINE ANALYSIS
3.12 STRUCTURAL HEART DEVICE REGULATORY APPROVAL ANALYSIS
3.13 PORTER’S FIVE FORCE ANALYSIS
  3.13.1 THREAT OF NEW ENTRANTS
  3.13.2 THREAT OF SUBSTITUTES
  3.13.3 BARGAINING POWER OF SUPPLIERS
  3.13.4 BARGAINING POWER OF BUYERS
  3.13.5 COMPETITIVE RIVALRY
3.14 SUPPLY CHAIN ANALYSIS
3.15 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  3.15.1 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE ANALYSIS
  3.15.2 MARKET SHARE ANALYSIS OF ANNULOPLASTY REPAIR DEVICES BY MAJOR PLAYERS
  3.15.3 MARKET SHARE ANALYSIS OF OCCLUDERS BY MAJOR PLAYERS
  3.15.4 MARKET SHARE ANALYSIS OF MECHANICAL VALVE REPLACEMENT DEVICES BY MAJOR PLAYERS
  3.15.5 MARKET SHARE ANALYSIS OF TISSUE VALVE REPLACEMENT DEVICES BY MAJOR PLAYERS
  3.15.6 MARKET SHARE ANALYSIS OF TRANSCATHETER AORTIC VALVE REPLACEMENT BY MAJOR PLAYERS
    3.15.6.1 Global TAVR devices market share analysis, by key players 2020 (%)
    3.15.6.2 Europe TAVR devices market share analysis, by key players 2020 (%)
    3.15.6.3 U.S. TAVR devices market share analysis, by key players 2020 (%)
  3.15.7 MARKET SHARE ANALYSIS OF VALVULOPLASTY REPAIR DEVICES BY MAJOR PLAYERS
3.16 STRUCTURAL HEART DEVICES MARKET PENETRATION, PREVALENCE, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED
3.17 STRUCTURAL HEART DEVICES NUMBER OF UNITS BY REGION
  3.17.1 OCCLUDERS NUMBER OF UNITS BY REGION
  3.17.2 TRANSCATHETER MITRAL VALVE REPAIR DEVICES NUMBER OF UNITS BY REGION
  3.17.3 SURGICAL VALVE REPAIR - ANNULOPLASTY DEVICES NUMBER OF UNITS BY REGION
  3.17.4 TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) DEVICES NUMBER OF UNITS BY REGION
  3.17.5 TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) DEVICES NUMBER OF UNITS BY REGION
  3.17.6 TRANSCATHETER PULMONARY VALVE REPLACEMENT (TPVR) DEVICES NUMBER OF UNITS BY REGION
3.18 TAVR CENTERS
3.19 STRUCTURAL HEART DEVICES COMPANY COMPARISON TABLE BY PRODUCTS
  3.19.1 TRANSCATHETER HEART VALVE COMPANY COMPARISON TABLE BY PRODUCT AND INDICATION
  3.19.2 OCCLUDERS COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
  3.19.3 VALVULOPLASTY COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
  3.19.4 ANNULOPLASTY COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
  3.19.5 MECHANICAL HEART VALVES COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION
  3.19.6 TISSUE HEART VALVES COMPANY COMPARISON TABLE BY PRODUCTS AND INDICATION

4 STRUCTURAL HEART DEVICES GLOBAL MARKET, BY PRODUCT

4.1 INTRODUCTION
4.2 STRUCTURAL HEART REPAIR DEVICES
  4.2.1 ANNULOPLASTY REPAIR DEVICES
  4.2.2 VALVULOPLASTY
  4.2.3 OCCLUDERS
  4.2.4 TRANSCATHETER MITRAL VALVE REPAIR DEVICES
  4.2.5 OTHER STRUCTURAL HEART REPAIR DEVICES
4.3 STRUCTURAL HEART VALVE REPLACEMENT DEVICES
  4.3.1 INTRODUCTION
  4.3.2 SURGICAL VALVE REPLACEMENT DEVICES
    4.3.2.1 Mechanical heart valves
    4.3.2.2 Tissue heart valves (biological valves)
  4.3.3 TRANSCATHETER VALVE REPLACEMENT DEVICES
    4.3.3.1 Transcatheter aortic valve replacement (TAVR)
    4.3.3.2 Transcatheter mitral valve replacement (TMVR)
    4.3.3.3 Transcatheter pulmonary valve replacement (TPVR)

5 STRUCTURAL HEART DEVICES GLOBAL MARKET, BY INDICATION

5.1 INTRODUCTION
5.2 HEART VALVE DISEASES
  5.2.1 MITRAL VALVE DISEASES
  5.2.2 AORTIC VALVE DISEASES
  5.2.3 OTHER HEART VALVE DISEASES
5.3 CONGENITAL HEART DISEASES
5.4 OTHER STRUCTURAL HEART DISEASES

6 REGIONAL ANALYSIS

6.1 INTRODUCTION
6.2 NORTH AMERICA
  6.2.1 U.S.
  6.2.2 REST OF NORTH AMERICA
6.3 EUROPE
  6.3.1 GERMANY
  6.3.2 ITALY
  6.3.3 FRANCE
  6.3.4 REST OF EUROPE
6.4 APAC
  6.4.1 JAPAN
  6.4.2 CHINA
  6.4.3 INDIA
  6.4.4 REST OF APAC
6.5 ROW
  6.5.1 BRAZIL
  6.5.2 TURKEY
  6.5.3 REST OF LATAM & MEA

7 COMPETITIVE LANDSCAPE

7.1 INTRODUCTION
7.2 PRODUCT APPROVALS
7.3 ACQUISITIONS
7.4 PRODUCT LAUNCH
7.5 PARTNERSHIPS
7.6 OTHER DEVELOPMENTS

8 MAJOR COMPANIES

8.1 ABBOTT LABORATORIES
  8.1.1 OVERVIEW
  8.1.2 FINANCIALS
  8.1.3 PRODUCT PORTFOLIO
  8.1.4 KEY DEVELOPMENTS
  8.1.5 BUSINESS STRATEGY
  8.1.6 SWOT ANALYSIS
8.2 ATRICURE, INC.
  8.2.1 OVERVIEW
  8.2.2 FINANCIALS
  8.2.3 PRODUCT PORTFOLIO
  8.2.4 KEY DEVELOPMENTS
  8.2.5 BUSINESS STRATEGY
  8.2.6 SWOT ANALYSIS
8.3 BOSTON SCIENTIFIC CORPORATION
  8.3.1 OVERVIEW
  8.3.2 FINANCIALS
  8.3.3 PRODUCT PORTFOLIO
  8.3.4 KEY DEVELOPMENTS
  8.3.5 BUSINESS STRATEGY
  8.3.6 SWOT ANALYSIS
8.4 CRYOLIFE, INC.
  8.4.1 OVERVIEW
  8.4.2 FINANCIALS
  8.4.3 PRODUCT PORTFOLIO
  8.4.4 KEY DEVELOPMENTS
  8.4.5 BUSINESS STRATEGY
  8.4.6 SWOT ANALYSIS
8.5 EDWARDS LIFESCIENCES CORPORATION
  8.5.1 OVERVIEW
  8.5.2 FINANCIALS
  8.5.3 PRODUCT PORTFOLIO
  8.5.4 KEY DEVELOPMENTS
  8.5.5 BUSINESS STRATEGY
  8.5.6 SWOT ANALYSIS
8.6 LIFETECH SCIENTIFIC CORPORATION
  8.6.1 OVERVIEW
  8.6.2 FINANCIALS
  8.6.3 PRODUCT PORTFOLIO
  8.6.4 KEY DEVELOPMENTS
  8.6.5 BUSINESS STRATEGY
  8.6.6 SWOT ANALYSIS
8.7 LIVANOVA PLC
  8.7.1 OVERVIEW
  8.7.2 FINANCIALS
  8.7.3 PRODUCT PORTFOLIO
  8.7.4 KEY DEVELOPMENTS
  8.7.5 BUSINESS STRATEGY
  8.7.6 SWOT ANALYSIS
8.8 MEDTRONIC PUBLIC LIMITED COMPANY
  8.8.1 OVERVIEW
  8.8.2 FINANCIALS
  8.8.3 PRODUCT PORTFOLIO
  8.8.4 KEY DEVELOPMENTS
  8.8.5 BUSINESS STRATEGY
  8.8.6 SWOT ANALYSIS
8.9 NUMED INC.
  8.9.1 OVERVIEW
  8.9.2 FINANCIALS
  8.9.3 PRODUCT PORTFOLIO
  8.9.4 KEY DEVELOPMENTS
  8.9.5 BUSINESS STRATEGY
  8.9.6 SWOT ANALYSIS
8.10 VENUS MEDTECH (HANGZHOU) INC.
  8.10.1 OVERVIEW
  8.10.2 FINANCIALS
  8.10.3 PRODUCT PORTFOLIO
  8.10.4 KEY DEVELOPMENTS
  8.10.5 BUSINESS STRATEGY
  8.10.6 SWOT ANALYSIS

LIST OF TABLES

TABLE 1 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 2 OCCLUDERS NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 3 TRANSCATHETER MITRAL VALVE REPAIR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 4 ANNULOPLASTY DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 5 TAVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 6 TMVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 7 TPVR DEVICES NUMBER OF UNITS, BY REGION, (2019-2027) (NO’S)
TABLE 8 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 9 STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 10 STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 11 ANNULOPLASTY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 12 VALVULOPLASTY GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 13 OCCLUDERS GLOBAL MARKET REGION, BY REGION, (2019-2027) ($MN)
TABLE 14 TRANSCATHETER MITRAL VALVE REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 15 OTHER STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 16 STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 17 STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 18 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 19 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 20 MECHANICAL HEART VALVES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 21 TISSUE HEART VALVES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 22 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 23 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 24 TRANSCATHETER AORTIC VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 25 TRANSCATHETER MITRAL VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 26 TRANSCATHETER PULMONARY VALVE REPLACEMENT GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 27 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
TABLE 28 HEART VALVE DISEASES GLOBAL MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
TABLE 29 HEART VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 30 MITRAL VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019 -2027) ($MN)
TABLE 31 AORTIC VALVE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 32 OTHER HEART VALVE DISEASES GLOBAL MARKET REGION, BY REGION, (2019-2027) ($MN)
TABLE 33 CONGENITAL HEART DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 34 OTHER STRUCTURAL HEART DISEASES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 35 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION, (2019-2027) ($MN)
TABLE 36 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 37 NORTH AMERICA STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 38 NORTH AMERICA STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 39 NORTH AMERICA SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 40 NORTH AMERICA TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 41 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
TABLE 42 NORTH AMERICA HEART VALVE DISEASE MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
TABLE 43 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 44 NORTH AMERICA TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 45 EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 46 EUROPE STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 47 EUROPE STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 48 EUROPE SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 49 EUROPE TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 50 EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
TABLE 51 EUROPE HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
TABLE 52 EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 53 EUROPE TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 54 APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 55 APAC STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 56 APAC STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 57 APAC SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 58 APAC TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 59 APAC STRUCTURAL HEART DISEASE MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
TABLE 60 APAC HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
TABLE 61 APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 62 APAC TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 63 ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, (2019-2027) ($MN)
TABLE 64 ROW STRUCTURAL HEART REPAIR DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 65 ROW STRUCTURAL HEART REPLACEMENT DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 66 ROW SURGICAL VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 67 ROW TRANSCATHETER VALVE REPLACEMENT MARKET REVENUE, BY PRODUCT TYPE, (2019-2027) ($MN)
TABLE 68 ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY INDICATION, (2019-2027) ($MN)
TABLE 69 ROW HEART VALVE DISEASES MARKET REVENUE, BY INDICATION TYPE, (2019-2027) ($MN)
TABLE 70 ROW STRUCTURAL HEART DEVICES MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 71 ROW TAVR MARKET REVENUE, BY COUNTRY, (2019-2027) ($MN)
TABLE 72 PRODUCT APPROVALS (2018 - 2020)
TABLE 73 ACQUISITIONS (2018 - 2020)
TABLE 74 PRODUCT LAUNCH (2018 - 2020)
TABLE 75 PARTNERSHIPS (2018 - 2020)
TABLE 76 OTHER DEVELOPMENTS (2018 - 2020)
TABLE 77 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
TABLE 78 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 79 ABBOTT LABORATORIES: TOTAL REVENUE, BY MEDICAL DEVICE SEGMENTS (2017-2019) ($MN)
TABLE 80 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY (2017-2019) ($MN)
TABLE 81 ATRICURE INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 82 ATRICURE INC.: TOTAL REVENUE BY PRODUCT SEGMENTS, (2017-2019) ($MN)
TABLE 83 ATRICURE INC.: TOTAL REVENUE BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 84 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
TABLE 85 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 86 BOSTON SCIENTIFIC CORPORATION: CARDIOVASCULAR REVENUE BY SUB-SEGMENTS, (2017-2019) ($MN)
TABLE 87 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 88 CRYOLIFE INC.: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 89 CRYOLIFE INC.: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
TABLE 90 CRYOLIFE INC.: MEDICAL DEVICES REVENUE BY, SUB-SEGMENTS, (2017-2019) ($MN)
TABLE 91 CRYOLIFE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 92 EDWARDS LIFESCIENCES CORP: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 93 EDWARDS LIFESCIENCES CORP: TOTAL REVENUE, BY PRODUCT SEGMENTS, (2017-2019) ($MN)
TABLE 94 EDWARDS LIFESCIENCES CORP: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 95 LIFETECH SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
TABLE 96 LIFETECH SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 97 LIFETECH SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 98 LIVANOVA PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 99 LIVANOVA PLC: TOTAL REVENUE, BY SEGMENTS (2017-2019) ($MN)
TABLE 100 LIVANOVA PLC: CARDIOVASCULAR REVENUE, BY SUB-SEGMENTS, (2017-2019) ($MN)
TABLE 101 LIVANOVA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 102 MEDTRONIC PLC: TOTAL SALES AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 103 MEDTRONIC PLC: TOTAL SALES, BY SEGMENTS, (2017-2019) ($MN)
TABLE 104 MEDTRONIC PLC: CARDIAC AND VASCULAR GROUP REVENUE, BY SUB-SEGMENTS, (2017-2019) ($MN)
TABLE 105 MEDTRONIC PLC: TOTAL SALES, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 106 VENUS MEDTECH: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 107 VENUS MEDTECH: TOTAL REVENUE, BY PRODUCT SEGMENTS, (2017-2019) ($MN)
TABLE 108 VENUS MEDTECH: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)

LIST OF FIGURES

FIGURE 1 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: STRUCTURAL HEART DEVICES GLOBAL MARKET
FIGURE 3 STRUCTURAL HEART DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 STRUCTURAL HEART DEVICES GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 STRUCTURAL HEART DEVICES GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 6 STRUCTURAL HEART DEVICES GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 STRUCTURAL HEART DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2015–2020)
FIGURE 9 STRUCTURAL HEART DEVICE GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 10 STRUCTURAL HEART DEVICES GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 11 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 12 ANNULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 13 OCCLUSION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 14 MECHANICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 15 TISSUE VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 16 TAVR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 17 TAVR DEVICES EUROPE MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 18 TAVR DEVICES U.S. MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 19 VALVULOPLASTY REPAIR DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2020 (%)
FIGURE 20 GLOBAL TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 21 U.S. TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 22 CHINA TAVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 23 GLOBAL TMVR AND TMVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 24 GLOBAL TPVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 25 CHINA TPVR MARKET PENETRATION, OPPORTUNITY AND NUMBER OF PROCEDURES PERFORMED, (2020)
FIGURE 26 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 27 STRUCTURAL HEART REPAIR DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 28 ANNULOPLASTY GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 29 TRANSCATHETER MITRAL VALVE REPAIR DEVICES GLOBAL MARKET SHARE, BY REGION, (2020 V/S 2027) (%)
FIGURE 30 STRUCTURAL HEART VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
FIGURE 31 SURGICAL VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
FIGURE 32 TRANSCATHETER VALVE REPLACEMENT DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2020 V/S 2027) (%)
FIGURE 33 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE, BY INDICATION (2020 V/S 2027) (%)
FIGURE 34 HEART VALVE DISEASES GLOBAL MARKET SHARE, BY INDICATION TYPE (2020 V/S 2027) (%)
FIGURE 35 STRUCTURAL HEART DEVICES GLOBAL MARKET REVENUE, BY REGION (2019-2027) ($MN), CAGR (%)
FIGURE 36 STRUCTURAL HEART DEVICES GLOBAL MARKET SHARE BY REGION AND MARKET REVENUE BY COUNTRY, (2020) (%) ($MN)
FIGURE 37 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 38 NORTH AMERICA STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 39 NORTH AMERICA STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 40 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
FIGURE 41 NORTH AMERICA STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 42 U.S. STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 43 REST OF NORTH AMERICA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 44 EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 45 EUROPE STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 46 EUROPE STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 47 EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
FIGURE 48 EUROPE STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 49 GERMANY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 50 ITALY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 51 FRANCE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 52 REST OF EUROPE STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 53 APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 54 APAC STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 55 APAC STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 56 APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
FIGURE 57 APAC STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 58 JAPAN STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 59 CHINA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 60 INDIA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 61 REST OF APAC STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 62 ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY PRODUCT (2020 V/S 2027) (%)
FIGURE 63 ROW STRUCTURAL HEART REPAIR DEVICES MARKET SHARE, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 64 ROW STRUCTURAL HEART REPLACEMENT MARKET SHARE, BY PRODUCT TYPE, SURGICAL AND TRANSCATHETER VALVE REPLACEMENT, BY PRODUCT TYPE (2020 V/S 2027) (%)
FIGURE 65 ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY INDICATION AND HEART VALVE DISEASE, BY INDICATION TYPE (2020) (%)
FIGURE 66 ROW STRUCTURAL HEART DEVICES MARKET SHARE, BY COUNTRY (2020 V/S 2027) (%)
FIGURE 67 BRAZIL STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 68 TURKEY STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 69 REST OF LATAM & MEA STRUCTURAL HEART DEVICES MARKET REVENUE, BY PRODUCT, INDICATION AND REPLACEMENT DEVICES, BY PRODUCT TYPE (2020 V/S 2027) ($MN)
FIGURE 70 KEY GROWTH STRATEGIES, (2018-2020)
FIGURE 71 SWOT: ABBOTT LABORATORIES
FIGURE 72 SWOT: ATRICURE INC.
FIGURE 73 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 74 SWOT: CRYOLIFE INC.
FIGURE 75 SWOT: EDWARDS LIFESCIENCES CORPORATION
FIGURE 76 SWOT: LIFETECH SCIENTIFIC
FIGURE 77 SWOT: LIVANOVA PLC
FIGURE 78 SWOT: MEDTRONIC PLC.
FIGURE 79 SWOT: NUMED INC.
FIGURE 80 SWOT: VENUS MEDTECH


More Publications